Jenoptik AG JEN.DE
Quarterly and annual results for Jenoptik stock (JEN.DE) since 2023: revenue, earnings, balance sheet, cash flow and management guidance from IR documents, every figure with its source. As of 08/2026, quarterly reporting. Latest reported (Q2 2026): Order backlog, EBITDA margin, Equity ratio. Latest reading: Margin expanding, Order intake, Guidance raised, Acquisition.
Published by Michael Wirl · About us · Methodology
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
Business Model#
What the company does and how it earns its money; written AI-editorially, exclusively from the company's original reports, without any assessment of our own.
Jenoptik is a photonics-based technology group headquartered in Jena, Germany, that develops and manufactures high-precision optical systems, sensors, laser modules, and related equipment for industrial and scientific customers. The group generates revenue across four reporting segments: Semiconductor & Advanced Manufacturing, supplying optical and inspection equipment for chip production; Biophotonics, serving medical technology, life science, and defense customers with photonic components and systems; Metrology & Production Solutions, providing measurement and quality-assurance systems predominantly for the automotive and other manufacturing industries; and Smart Mobility Solutions, delivering intelligent traffic management and mobility systems. Revenue depends substantially on capital expenditure cycles in the semiconductor and automotive industries, and the customer base is concentrated among larger industrial enterprises and original equipment manufacturers.
Current Status#
Summary of the most recent reporting period: core figures, drivers and management statements; written editorially from the current original report, every figure backed by a source number.
Price & Chart#
Interactive price chart (TradingView) and the trend of key figures from the core tables. The price chart loads only after a click; at that point a connection to TradingView is established.
Daily candles with news and earnings markers. Loads only on click.
Share-Price Drivers#
Factors the company itself names as material for its business development (IR-based); reproduced neutrally, no price forecast and no assessment of our own.
It is the largest and most profitable segment (revenue 108.2, margin 30.6, growth +7.2% in 2026-Q1) and underpins group operating income of 36 in 2026-Q2 29 128
Largest segment with revenue 108.2 and a 30.6 margin, growth +7.2%; capacity added via the Dresden micro-optics/high-tech fab launched in 2025 and planned semiconductor-optics expansion at Jena 29 27 22
Revenue 31.8 with growth +10.9%; traffic-enforcement systems deployed in Jordan and UAB Fima ITS (now JENOPTIK Baltic) acquired in 2026-03 29 27 28
Segment revenue 56.8 with growth of -10.9%, though margin held at 21.9 29
Revenue 39.1 with growth -3.7% and a margin of -0.4, the weakest of the four units 29
Operating income of 36 on revenue of 262 in 2026-Q2, up from 22.7 a year earlier, with guidance raised 128 29
Recent launches include the F-Theta lens for additive manufacturing, the MS-I² multispectral imaging solution and the MBSS modular beam-splitting system in 2025 22 27
Sector trend: Photonics demand is diverging: semiconductor-optics and smart-mobility demand is rising with high or improving margins, while life-science (Biophotonics) and metrology demand is softer. Group margins and utilisation are trending higher, supported by raised guidance 29 128
Event Timeline#
This timeline collects the material events from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements. Events are grouped by quarter (most recent first); the grey tag before each event names the event type, the date is the publication date of the source. Management quotes open the quarter block as direct quotes. Per quarter we show the three most defining events; more can be expanded per quarter, older years are collapsed. Every event carries its source as a superscript, clickable number.
2026 · 7 events
2026-Q2 · Apr – Jun 2026
EBITDA rose 25.5% to 98.9 million euros with EBITDA margin expanding to 19.7% from 15.8% in the prior-year period 28
Executive Board raises full-year guidance to revenue in upper half of single-digit percentage range and EBITDA margin of 20.0-21.0% 28
Acquisition of UAB Fima ITS (now UAB JENOPTIK Baltic) completed March 2, 2026, adding intelligent transportation systems business 28
2026-Q1 · Jan – Mar 2026
Order intake increased 74.4% to 356.9 million euros, including a major order in Semiconductor & Advanced Manufacturing; backlog rose 21.7% to 719.2 million euros with book-to-bill of 1.48 29
EBITDA rose 22.5% to 44.4 million euros with margin improving to 18.4%, driven by higher capacity utilization and favorable product mix in semiconductors 29
Executive Board confirms full-year guidance for single-digit revenue growth and EBITDA margin of 19.0-21.0% 29
2025 · 12 events
2025-Q4 · Oct – Dec 2025
Full-year revenue declined 6.3% to 1,046 million euros due to lower demand in the semiconductor lithography supply chain and challenging automotive market; Biophotonics grew 10.4% and Smart Mobility Solutions grew 8.5% 27
Executive Board expects revenue growth in single-digit percentage range for 2026 with EBITDA margin between 19.0 and 21.0 percent 27
Dr. Stefan Traeger announced resignation from Executive Board effective February 15, 2026 after nine years as Chairman; Daniela Mattheus elected Chairwoman of Supervisory Board effective December 30, 2025 27
2025-Q3 · Jul – Sep 2025
Nine-month revenue declined 7.6% to 753.2 million euros, with Semiconductor & Advanced Manufacturing down 15.2% and Metrology & Production Solutions down 11.3%; order intake nearly flat with book-to-bill improving to 1.03 26
Nine-month EBITDA margin compressed to 17.5% from 19.7% in the prior-year period, impacted by lower utilization and product mix changes in Semiconductor & Advanced Manufacturing 26
Executive Board expects revenue and EBITDA margin at lower end of guidance ranges for 2025 due to persistent market uncertainty and ongoing cost reduction measures 18
2025-Q2 · Apr – Jun 2025
H1 order intake fell 9.9% to 472.7 million euros; SBU Semiconductor & Advanced Manufacturing revenue declined 15.1% due to supply chain fluctuations and reduced lithography area revenue 16
Executive Board revised 2025 guidance to lower half of minus 5 to plus 5 percent revenue range and EBITDA margin to lower half of 18.0 to 21.0 percent range 16
Prodomax divestment postponed; sale no longer feasible by end of 2025 due to ongoing challenges in North American automotive sector 16
2025-Q1 · Jan – Mar 2025
EBITDA margin compressed to 14.9% from 17.4% in Q1 2024, driven by lower utilization and product mix changes in Semiconductor & Advanced Manufacturing 17
Group reorganized into four Strategic Business Units effective January 1, 2025, replacing prior matrix organization 17
Revenue declined to 243.6 million euros in Q1 2025 and order intake fell 15.5% to 204.6 million euros, driven primarily by lower demand in the semiconductor equipment sector 25
2024 · 13 events
2024-Q4 · Oct – Dec 2024
FY2024 revenue grew 4.7% to 1,115.8 million euros, driven by semiconductor equipment business in Advanced Photonic Solutions 14
FY2024 EBITDA margin reached 19.9%, at the upper end of the guidance range of 19.5 to 20.0 percent 15
Advanced Photonic Solutions reorganized effective January 1, 2025 into four segments: Semiconductor & Advanced Manufacturing, Biophotonics, Metrology & Production Solutions, and Smart Mobility Solutions, to increase customer focus and efficiency 12
2024-Q3 · Jul – Sep 2024
Nine-month EBITDA rose 12.2% to 160.6 million euros with EBITDA margin improving to 19.7% from 18.6% in the prior year 11
FY2024 revenue and earnings guidance confirmed: mid-single-digit growth and EBITDA margin of 19.5 to 20.0 percent 11
FY2025 financial targets postponed to FY2026: revenue of around 1.2 billion euros and EBITDA margin of 21 to 22 percent, due to challenging market environment 11
2024-Q2 · Apr – Jun 2024
Operating cash flow reached 35.1 EURm vs 6.2 EURm in 2023-Q2 (×5.7). 24
H1 2024 EBITDA improved 10.7% to 101.4 million euros with margin reaching 18.8% 9
FY2024 guidance confirmed: mid-single-digit revenue growth and EBITDA margin of 19.5 to 20.0 percent 9
2024-Q1 · Jan – Mar 2024
Revenue increased 9.4% to 256.1 million euros, driven by Advanced Photonic Solutions, particularly Semiconductor Equipment 10
Capital expenditure for new semiconductor production facility in Dresden initiated, with 90 to 100 million euros planned for a production building and office complex 10
FY2024 guidance initiated: organic revenue growth in mid-single-digit percentage range; EBITDA margin 19.5-20.0% including approximately 0.5 percentage point charge for Dresden plant relocation 4
2023 · 11 events
2023-Q4 · Oct – Dec 2023
Net income rose 28.8% to 73.5 million euros; earnings per share increased from 0.96 euros to 1.27 euros 5
FY EBITDA margin reached 19.7%, up from 18.8% in 2022, as EBITDA improved to 209.6 million euros 8
2023-Q3 · Jul – Sep 2023
9M free cash flow more than doubled to 56.9 million euros from 28.4 million euros in prior year 2
9M revenue increased 10.1% to 768.7 million euros with EBITDA margin improving to 18.6% from 16.9% in prior year 2
EBITDA margin guidance raised to around 19.5% for FY2023, from prior range of 19.0-19.5% 2
2023-Q2 · Apr – Jun 2023
H1 EBITDA margin improved to 18.1% from 15.6% in prior year as H1 EBITDA rose 31.6% to 91.6 million euros 6
FY2023 guidance confirmed: revenue 1,050-1,100 million euros and EBITDA margin 19.0-19.5% 1
50% stake in HILLOS GmbH sold to Hilti Aktiengesellschaft; contract signed July 13, 2023 to acquire 33.34% stake in JENOPTIK Korea Corporation Ltd. 1
2023-Q1 · Jan – Mar 2023
EBITDA rose 74.2% to 36.6 million euros with margin improving to 15.6% from 10.1% 3
Revenue increased 12.2% to 234.1 million euros, particularly driven by the Advanced Photonic Solutions division 3
FY2023 guidance confirmed: revenue 1,050-1,100 million euros and EBITDA margin 19.0-19.5% 3
Key Figures (€m)#
The company's core financial figures in three views, one below the other: fiscal years (as reported; after restatements the table shows the most recent filing version, marked), half-years (6-month basis, H2 = second half on its own) and quarters (3-month basis, not cumulative). Each row is one period, most recent first. Values with a dotted underline are clickable and show the raw value, the exact source location, the scale evidence and the source; derived values additionally show their formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Net income | EPS (€) | OCF | Source |
|---|---|---|---|---|---|---|
| FY2025 | 1,046° | 114.5EBIT | 74.2 | 1.26 | 196 | 27 |
| FY2024 | 1,115.8° | 146.6EBIT | 94.2 | 1.62 | 167.1 | 12 |
| FY2023 | 1,066 | 126.3EBIT | 73.5 | 1.27 | 167 | 115 |
Quarters
| Period | Published | Revenue | Op. income | Net income | EPS (€) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-11 | 262 | 36EBIT | 22.9 | 0.40≈ | 25.1 | 126.4 | 307.5 | 128 |
| 2026-Q1* | 2026-06-30 | 241.2 | 25.9EBIT | 16.8 | 0.29≈ | 12.6 | – | 313 | 29 |
| 2025-Q4* | 2025-06-30 | 292.8 | 41.6EBIT | 27.3 | 0.46≈ | 60 | 5.1~ | 330.8~ | 23 |
| 2025-Q3* | 2025-11-11 | 254.8 | 33.3EBIT | 21.7 | 0.37 | 27.2 | – | – | 18 |
| 2025-Q2* | 2025-08-12 | 254.8 | 22.7EBIT | 16.1 | 0.26 | 0.8 | 41.3 | 344.4 | 16 |
| 2025-Q1* | 2025-03-31 | 243.6 | 16.9EBIT | 9.2 | 0.16 | 30.7 | 50.2 | 383.3 | 29 |
| 2024-Q4* | 2025-03-25 | 300.7 | 42EBIT | 27.4 | 0.47≈ | 16.9 | 84.9 | 396.2 | 23 |
| 2024-Q3* | 2024-11-11 | 274.3 | 40.9EBIT | 26.6 | 0.46 | 14.4~ | 57.9 | 421.4 | 11 |
| 2024-Q2* | 2024-06-30 | 284.7 | 37.7EBIT | 24.8 | 0.42 | 20.2~ | 60.1 | 429.6 | 24 |
| 2024-Q1* | 2024-06-30 | 256.1 | 26EBIT | 15.4 | 0.27 | 15.6 | 56.5 | 416.7 | 17 |
| 2023-Q4* | 2024-03-27 | 297.3 | 38.2EBIT | 19.6 | 0.32≈ | 49.4 | 67.7 | 423.1 | 5 |
| 2023-Q3* | 2023-09-30 | 263.8 | 34.3EBIT | 21.5 | 0.38≈ | 17.2~ | 34.6 | 489.7 | 7 |
| 2023-Q2* | 2023-06-30 | 270.8 | 33.9EBIT | 20.9 | 0.35≈ | -13 | 49.1 | 502.1 | 9 |
| 2023-Q1* | 2023-06-30 | 234.1 | 19.9EBIT | 11.8 | 0.21≈ | 25.4 | – | – | 103 |
Balance Sheet & Cash Flow (€m)#
Point-in-time balance sheet items (e.g. cash, financial debt) and cash flow items (operating cash flow, investments/capex) per fiscal year, half-year and quarter. Balance sheet values are as of the period end, flow items cover the period. Derived values are marked and are calculated, for example, as: net debt = financial debt − cash; free cash flow = operating cash flow − capex; the click popover shows formula and inputs. All values are extracted automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original.
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2025-06-30 | 5.1~ | 335.9 | 330.8~ | 77.2 | 196 | 77.4 | 118.6 | 27 |
| FY2024 | 2025-03-19 | 84.9 | 481.1 | 396.2~ | 74.9 | 167.1 | 114.6 | 52.5 | 12 |
| FY2023 | 2023-12-31 | 67.7 | 490.8 | 423.1~ | 70.9 | 167 | 110.4 | 56.6 | 115 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-11 | 126.4 | 376.7 | 307.5 | – | 34.7 | 9.6 | 25.1 | 128 |
| 2026-Q1 | 2026-06-30 | – | 394.2 | 313 | – | 22.7 | 10.1 | 12.6 | 29 |
| 2025-Q4 | 2025-06-30 | 5.1~ | 335.9 | 330.8~ | – | 79.1 | 19.1 | 60 | 23 |
| 2025-Q3 | 2025-11-11 | – | – | – | – | 52.8 | 25.6 | 27.2 | 18 |
| 2025-Q2 | 2025-08-12 | 41.3 | 385.7 | 344.4 | 59.5 | 19 | 18.2 | 0.8 | 16 |
| 2025-Q1 | 2025-03-31 | 50.2 | 433.4 | 383.3 | 19.3 | 45.1 | 14.4 | 30.7 | 29 |
| 2024-Q4 | 2025-03-25 | 84.9 | 481.1 | 396.2 | 18.9 | 58.9 | 42 | 16.9 | 23 |
| 2024-Q3 | 2024-11-11 | 57.9 | 480.1 | 421.4 | 18.3 | 40.8 | 26.4~ | 14.4~ | 11 |
| 2024-Q2 | 2024-06-30 | 60.1 | 424.8 | 429.6 | 19.3 | 35.1 | 14.9~ | 20.2~ | 24 |
| 2024-Q1 | 2024-06-30 | 56.5 | – | 416.7 | 18.5 | 32.3 | 16.7 | 15.6 | 17 |
| 2023-Q4 | 2024-03-27 | 67.7 | 490.8 | 423.1 | 19.7 | 81.9 | 32.5 | 49.4 | 5 |
| 2023-Q3 | 2023-09-30 | 34.6 | 524.3 | 489.7 | 17.4 | 34.6 | 17.3~ | 17.2~ | 7 |
| 2023-Q2 | 2023-06-30 | 49.1 | 551.3 | 502.1 | 17.1 | 6.2 | 19.1 | -13 | 9 |
| 2023-Q1 | 2023-06-30 | – | – | – | 16.6 | 44.4 | 19.1 | 25.4 | 103 |
Revenue by Type (as of 2026-Q2 · EURm · 9/11)#
Revenue split by segment or product type, exactly as the company itself reports it. The basis is stated next to each value (3, 6 or 12 months); segment totals can deviate from group revenue (reconciliation/consolidation items). If the company changes its segment structure, older structures are kept in the expandable part. Rows in grey are no longer reported separately by the company; they show the last available figures and are never extrapolated.
| Segment | Since | Period | Basis | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|---|---|
| Semiconductor & Advanced Manufacturing | 2024-H1 | 2026-Q1 | 3M | 108.2 | 7.2% | 30.6% | 29 |
| Biophotonics | 2024-H1 | 2026-Q1 | 3M | 56.8 | -10.9% | 21.9% | 29 |
| Metrology & Production Solutions | 2024-H1 | 2026-Q1 | 3M | 39.1 | -3.7% | -0.4% | 29 |
| Smart Mobility Solutions | FY2022 | 2026-Q1 | 3M | 31.8 | 10.9% | 11.6% | 29 |
| Europe | FY2024 | FY2025 | 12M | 564.3 | – | – | 19 |
| Americas | FY2024 | FY2025 | 12M | 253.7 | – | – | 19 |
| Asia/Pacific | FY2024 | FY2025 | 12M | 175.7 | – | – | 19 |
| Middle East/Africa | FY2024 | FY2025 | 12M | 52.3 | – | – | 19 |
| Other | FY2022 | FY2025 | 12M | 29.9 | – | – | 27 |
| Advanced Photonic Solutions | FY2022 | FY2024 | 3M | – | 5.6% | 21.8% | 15 |
| Non-Photonic Portfolio Companies | FY2022 | FY2024 | 3M | – | 4% | 17.5% | 15 |
Products & M&A (9/20 active+recent)#
Product announcements from the reports; market launches, approvals, partnerships; with first mention (date) and source. “Active/current” means: still mentioned in the most recent reports; what the company no longer mentions moves to the expandable part but is never deleted. Rows in grey are discontinued products.
| Product/Line | Since | Status | Source |
|---|---|---|---|
| New high-tech fab at Airportpark Dresden | 2025-01 | Launched | 8 |
| Traffic enforcement systems deployment in Jordan | 2025 | Launched | 27 |
| Semiconductor optics production capacity expansion at Jena (3x) | 2025 | Launched | 27 |
| MS-I2 multispectral illumination and imaging solution | 2025 | Launched | 27 |
| MBSS Modular Beam Splitting System | 2025 | Launched | 27 |
| F-Theta lens for additive manufacturing (2x) | 2025 | Launched | 22 |
| Expansion of production capacities for high-quality classic semiconductor optics at headquarters in Jena | 2025 | Launched | 20 |
| Expansion of human rights audits within supply chain planned | 2025 | Planned | 15 |
| Dresden factory expansion (8x) | 2025 | Launched | 20 |
| JENscan Style translucent technology first delivery | 2024-08 | Launched | 15 |
| 400th JENOPTIK-VOTAN® A system delivery | 2024-07 | Launched | 15 |
| Regional matrix dissolution and verticalization in Advanced Photonic Solutions | 2024 | Launched | 4 |
| On-site human rights audits initiated | 2024 | Launched | 15 |
| PSS-40/LCLW test station innovation award at Blechexpo | 2023-11 | Launched | 8 |
| UFO Probe Card development for wafer-level photonic integrated circuit testing | 2023 | Launched | 8 |
| JENar Silverline lens launch for laser material processing of solar cells | 2023 | Launched | 8 |
| JENOPTIK Industrial Metrology Germany GmbH integrated management system recertification (ISO 9001/ISO 14001/ISO 45001) | 2023 | Launched | 8 |
| JENOPTIK Automatisierungstechnik GmbH ISO 14001 certification | 2023 | Launched | 8 |
| Berlin medical technology site (4x) | 2023 | Launched | 1 |
M&A (16)#
All recorded acquisitions (purchases) and divestitures/exits with date, short description and source; deliberately including smaller transactions that summaries often miss. Purchase prices appear only where the company itself has disclosed them. Rows in grey are cancelled transactions; the cancellation date is shown in the row.
Acquisitions
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| New debenture bond tranches (150 million euros total) | 2026-04 | Completed | 28 |
| UAB Fima ITS (now UAB JENOPTIK Baltic) | 2026-03 | Completed | 28 |
| Cleanroom factory in Dresden (5x) | 2024-01 | Completed | 27 |
| TELSTAR-HOMMEL Corporation Ltd. stake sale (8x) | 2023 | Completed | 8 |
| Prodomax major welding robots order for North America (2x) | 2023 | Completed | 2 |
| Goodwill reallocation to HOMMEL ETAMIC and Prodomax | 2023 | Completed | 8 |
| BG Medical GmbH acquisition | 2023 | Completed | 8 |
| Jenoptik joined the UN Global Compact | 2021 | Completed | 15 |
Divestitures / exits
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| HOMMEL ETAMIC internal development instead of divestiture | 2024-06 | Divested | 11 |
| Prodomax sale (4x) | 2024 | Divested | 16 |
| Sale of 50-percent stake in HILLOS GmbH to Hilti Aktiengesellschaft | 2023-06 | Divested | 8 |
| HILLOS GmbH stake sale | 2023-06 | Divested | 1 |
| Prodomax divestiture | 2023 | Divested | 8 |
| Medium-term intention to sell Prodomax | 2023 | Divested | 8 |
| Automation & Integration business (Prodomax brand) disposal | 2023 | Divested | 8 |
| VINCORION discontinued operation deconsolidation | 2022-06 | Divested | 8 |
Reported KPIs (as disclosed) (402)#
Figures the company discloses itself in addition to the standard financials; order intake, recurring revenue, user or unit counts, adjusted measures. These “story KPIs” usually slip through standard databases; here they are collected as reported, with no calculation of our own. Important: the definition comes from the company itself and can differ from firm to firm; period and source are stated next to every value.
| Date | Period | KPI | Value / change | Source |
|---|---|---|---|---|
| 2026-08-11 | 2026-Q2 | Working capital ratio | 32.3 | 28 |
| 2026-08-11 | 2026-Q2 | Order backlog | 824.8 (EUR in million euros) | 28 |
| 2026-08-11 | 2026-Q2 | Leverage (Net debt/EBITDA) | 1.4x | 28 |
| 2026-08-11 | 2026-Q2 | Gross margin | 36.1 | 28 |
| 2026-08-11 | 2026-Q2 | Equity ratio | 58.4 | 28 |
| 2026-08-11 | 2026-Q2 | EBITDA margin | 19.7 | 28 |
| 2026-08-11 | 2026-Q2 | EBIT margin | 12.3 | 28 |
| 2026-08-11 | 2026-Q2 | Cash conversion rate | 47.7 | 28 |
| 2026-08-11 | 2026-Q2 | Book-to-bill ratio | 1.44 | 28 |
| 2026-05-11 | 2026-Q1 | Working capital ratio | 31.8 | 29 |
| 2026-05-11 | 2026-Q1 | Order backlog | 719.2 (EUR in million euros) | 29 |
| 2026-05-11 | 2026-Q1 | Leverage | 1.6x | 29 |
| 2026-05-11 | 2026-Q1 | Gross margin | 35.4 | 29 |
| 2026-05-11 | 2026-Q1 | Equity ratio | 60.4 | 29 |
| 2026-05-11 | 2026-Q1 | EBITDA margin | 18.4 | 29 |
| 2026-05-11 | 2026-Q1 | Cash conversion rate | 35.9 | 29 |
| 2026-05-11 | 2026-Q1 | Book to bill ratio | 1.48 | 29 |
| 2026-03-18 | FY2025 | Working capital ratio | 29.1 | 27 |
| 2026-03-18 | FY2025 | Working capital | 304.6 (EUR million euros) | 27 |
| 2026-03-18 | FY2025 | Work related illnesses | 2 | 27 |
| 2026-03-18 | FY2025 | Work related accidents rate | 4.5 | 27 |
| 2026-03-18 | FY2025 | Work related accidents count | 32 | 27 |
| 2026-03-18 | FY2025 | Women in middle senior management | 33.3 | 27 |
| 2026-03-18 | FY2025 | Suppliers medium sized | approximately 20 | 27 |
| 2026-03-18 | FY2025 | Suppliers global base countries | 57 | 27 |
| 2026-03-18 | FY2025 | Supplier audits conducted | 45 | 27 |
| 2026-03-18 | FY2025 | Renewable electricity share | 96.8 % | 27 |
| 2026-03-18 | FY2025 | Personnel expenses | 404.8 (EUR million euros) | 27 |
| 2026-03-18 | FY2025 | Payout ratio | 31.7² | 27 |
| 2026-03-18 | FY2025 | Organic revenue growth | -6.3% | 27 |
| 2026-03-18 | FY2025 | Order backlog | 590.8 (EUR million euros) | 27 |
| 2026-03-18 | FY2025 | Lost workdays | 290 | 27 |
| 2026-03-18 | FY2025 | Leverage | 1.6 | 27 |
| 2026-03-18 | FY2025 | Highest paid to median ratio | 19.7 | 27 |
| 2026-03-18 | FY2025 | Gross profit | 336.3 (EUR million euros) | 27 |
| 2026-03-18 | FY2025 | Fines for corruption | 0 | 27 |
| 2026-03-18 | FY2025 | Fatal work accidents | 0 | 27 |
| 2026-03-18 | FY2025 | Equity ratio | 60.2 | 27 |
| 2026-03-18 | FY2025 | Dividend yield | 2.0² | 27 |
| 2026-03-18 | FY2025 | Dividend per share | 0.40² | 27 |
| 2026-03-18 | FY2025 | Debt-to-equity ratio | 0.66 | 27 |
| 2026-03-18 | FY2025 | CSR rate | 64 | 27 |
| 2026-03-18 | FY2025 | Corruption and bribery cases | 0 | 27 |
| 2026-03-18 | FY2025 | Cash conversion rate | 79.2% | 27 |
| 2026-03-18 | FY2025 | Voluntary turnover rate | 4.5 % | 27 |
| 2026-03-18 | FY2025 | Turnover rate | 9.6 % | 27 |
| 2026-03-18 | FY2025 | Trainees and dual-study students | 201 | 27 |
| 2026-03-18 | FY2025 | Trainees and dual-study students (prior year) | 178 | 27 |
| 2026-03-18 | FY2025 | Trainees and dual-study students | 201 | 27 |
| 2026-03-18 | FY2025 | Total training hours | 38,991 hours | 27 |
| 2026-03-18 | FY2025 | Total renewable energy consumption | 50,598 | 27 |
| 2026-03-18 | FY2025 | Total indirect (Scope 3) GHG emissions | 197,025 t CO2e | 27 |
| 2026-03-18 | FY2025 | Total energy consumption | 72,293 | 27 |
| 2026-03-18 | FY2025 | Taxonomy-eligible revenue share | 40.5 % | 27 |
| 2026-03-18 | FY2025 | Taxonomy-eligible OpEx share | 48.5 % | 27 |
| 2026-03-18 | FY2025 | Taxonomy-eligible CapEx share | 55.0 % | 27 |
| 2026-03-18 | FY2025 | Taxonomy-aligned revenue share | 0.0 % | 27 |
| 2026-03-18 | FY2025 | Taxonomy-aligned OpEx share | 0.0 % | 27 |
| 2026-03-18 | FY2025 | Taxonomy-aligned CapEx share | 0.0 % | 27 |
| 2026-03-18 | FY2025 | Share of renewable sources in total energy consumption | 70.0 % | 27 |
| 2026-03-18 | FY2025 | Scope 2 GHG emissions (location-based) | 1,267 t CO2e | 27 |
| 2026-03-18 | FY2025 | Scope 1 GHG emissions | 2,903 t CO2e | 27 |
| 2026-03-18 | FY2025 | Reports related to human rights violations | 0 | 27 |
| 2026-03-18 | FY2025 | Reports related to discrimination issues | 15 | 27 |
| 2026-03-18 | FY2025 | ROCE prior year | 10.8% | 27 |
| 2026-03-18 | FY2025 | ROCE | 8.4% | 27 |
| 2026-03-18 | FY2025 | R&D ratio 2 prior year | 5.7% | 27 |
| 2026-03-18 | FY2025 | R&D ratio 2 | 5.9% | 27 |
| 2026-03-18 | FY2025 | R&D ratio 1 prior year | 9.5% | 27 |
| 2026-03-18 | FY2025 | R&D ratio 1 | 10.6% | 27 |
| 2026-03-18 | FY2025 | R&D output prior year | 106.5 million euros | 27 |
| 2026-03-18 | FY2025 | R&D output | 111.2 million euros | 27 |
| 2026-03-18 | FY2025 | Proportion of women prior year | 30.3% | 27 |
| 2026-03-18 | FY2025 | Proportion of women | 30.6% | 27 |
| 2026-03-18 | FY2025 | Proportion of employees abroad prior year | 36.1% | 27 |
| 2026-03-18 | FY2025 | Proportion employees abroad | 36.0% | 27 |
| 2026-03-18 | FY2025 | Property plant equipment net prior year | 419,917 | 27 |
| 2026-03-18 | FY2025 | Property plant equipment net | 426,196 | 27 |
| 2026-03-18 | FY2025 | Plan assets prior year | 136,078 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Plan assets | 144,419 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Other reports related to social factors | 13 | 27 |
| 2026-03-18 | FY2025 | Order backlog prior year | 670.1 million euros | 27 |
| 2026-03-18 | FY2025 | Order backlog | 590.8 (EUR in million euros) | 27 |
| 2026-03-18 | FY2025 | Order backlog | 590.8 million euros | 27 |
| 2026-03-18 | FY2025 | Leverage | 1.6x | 27 |
| 2026-03-18 | FY2025 | Lease ROU assets net prior year | 62,042 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Lease ROU assets net | 65,617 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Interns | 9 | 27 |
| 2026-03-18 | FY2025 | Gross margin prior year | 33.4% | 27 |
| 2026-03-18 | FY2025 | Gross margin | 32.1% | 27 |
| 2026-03-18 | FY2025 | GHG intensity (market-based) | 192.4 t CO2e/million euros revenue | 27 |
| 2026-03-18 | FY2025 | GHG intensity (location-based) | 207.0 t CO2e/million euros revenue | 27 |
| 2026-03-18 | FY2025 | GHG emissions Scope 1+2 reduction vs 2019 | 59.0 % | 27 |
| 2026-03-18 | FY2025 | Equity ratio | 60.2 | 27 |
| 2026-03-18 | FY2025 | Equity ratio | 60.2% | 27 |
| 2026-03-18 | FY2025 | Energy intensity (climate-intensive sectors) | 69.1 | 27 |
| 2026-03-18 | FY2025 | Employees abroad prior year | 1,677 | 27 |
| 2026-03-18 | FY2025 | Employees abroad | 1,602 | 27 |
| 2026-03-18 | FY2025 | EBITDA margin prior year | 19.9% | 27 |
| 2026-03-18 | FY2025 | EBITDA margin | 18.4% | 27 |
| 2026-03-18 | FY2025 | EBIT margin prior year | 13.1% | 27 |
| 2026-03-18 | FY2025 | EBIT margin | 10.9% | 27 |
| 2026-03-18 | FY2025 | Dividend per share | 0.40 | 27 |
| 2026-03-18 | FY2025 | Defined benefit obligations prior year | 143,198 | 27 |
| 2026-03-18 | FY2025 | Defined benefit obligations | 148,727 | 27 |
| 2026-03-18 | FY2025 | Debt to equity ratio prior year | 0.80 | 27 |
| 2026-03-18 | FY2025 | Debt to equity ratio | 0.66 | 27 |
| 2026-03-18 | FY2025 | Coverage rate of employees | 44.0 % | 27 |
| 2026-03-18 | FY2025 | Contract liabilities prior year | 60,308 | 27 |
| 2026-03-18 | FY2025 | Contract liabilities | 52,819 | 27 |
| 2026-03-18 | FY2025 | Contract asset prior year | 86,835 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Contract asset | 83,997 (EUR in thousand euros) | 27 |
| 2026-03-18 | FY2025 | Confirmed cases of discrimination | 2 | 27 |
| 2026-03-18 | FY2025 | Combined Scope 1 and market-based Scope 2 GHG emissions | 4,171 t CO2e | 27 |
| 2026-03-18 | FY2025 | Cash conversion rate prior year | 46.5% | 27 |
| 2026-03-18 | FY2025 | Cash conversion rate | 79.2 | 27 |
| 2026-03-18 | FY2025 | Cash conversion rate | 79.2% | 27 |
| 2026-03-18 | FY2025 | CO2 emissions Scope 1 2 2025 | 4,171 t CO2e | 27 |
| 2026-03-18 | FY2025 | Book to bill ratio prior year | 0.92 | 27 |
| 2026-03-18 | FY2025 | Book to bill ratio | 0.95 | 27 |
| 2026-03-18 | FY2025 | Available liquidity prior year | approximately 480 million euros | 27 |
| 2026-03-18 | FY2025 | Available liquidity | approximately 480 million euros | 27 |
| 2026-03-18 | FY2025 | Agency workers | 42 | 27 |
| 2026-03-18 | FY2025 | Absenteeism rate Germany prior year | 5.8% | 27 |
| 2026-03-18 | FY2025 | Absenteeism rate Germany | 5.8% | 27 |
| – | FY2025 | Net debt to EBITDA | 1.6x | 22 |
| – | FY2025 | market capitalization year end | 1,120.1 (EUR million euros) | 22 |
| – | FY2025 | Equity ratio | around 60 percent | 20 |
| – | FY2025 | Equity ratio | 60 percent | 22 |
| – | FY2025 | Dividend per share | 0.40 euros | 20 |
| – | FY2025 | Dividend per share | 0.40 | 22 |
| – | FY2025 | CO2 emissions reduction | 59 percent | 20 |
| 2026-03-18 | 2025-Q4 | Working capital | 304,578 (EUR in thousand euros) | 19 |
| 2026-03-18 | 2025-Q4 | Order backlog | 590,762 (EUR in thousand euros) | 19 |
| 2026-03-18 | 2025-Q4 | Unused credit facility | 398,026 | 19 |
| 2026-03-18 | 2025-Q4 | Total financial liabilities | 500,614 | 19 |
| 2026-03-18 | 2025-Q4 | Total financial assets | 219,198 (EUR in thousand euros) | 19 |
| 2025-11-12 | 2025-Q3 | Order backlog | 658.9 (EUR in million euros) | 26 |
| 2025-11-11 | 2025-Q3 | Working capital ratio | 30.3 | 18 |
| 2025-11-11 | 2025-Q3 | Working capital | 319.8 (EUR in million euros) | 18 |
| 2025-11-11 | 2025-Q3 | Unused credit lines | 370 | 18 |
| 2025-11-11 | 2025-Q3 | Order backlog | 658.9 (EUR in million euros) | 18 |
| 2025-11-11 | 2025-Q3 | Net debt | 366.3 (EUR in million euros) | 18 |
| 2025-11-11 | 2025-Q3 | Leverage | 1.9 | 18 |
| 2025-11-11 | 2025-Q3 | Gross margin | 31.9 | 18 |
| 2025-11-11 | 2025-Q3 | Equity ratio | 59.1 | 18 |
| 2025-11-11 | 2025-Q3 | Cash conversion rate | 64.2 | 18 |
| 2025-11-11 | 2025-Q3 | Cash and cash equivalents | 51.0 (EUR in million euros) | 18 |
| 2025-11-11 | 2025-Q3 | Book-to-bill ratio Q3 | 1.20 | 18 |
| 2025-11-11 | 2025-Q3 | Book-to-bill ratio | 1.03 | 18 |
| 2025-11-11 | 2025-Q3 | EBITDA margin | 17.5 | 18 |
| 2025-11-11 | 2025-Q3 | EBIT margin | 9.7 | 18 |
| 2025-08-13 | 2025-H1 | Order backlog | 612.7 (EUR in million euros) | 24 |
| 2025-08-12 | 2025-Q2 | Working capital ratio | 30.3% | 16 |
| 2025-08-12 | 2025-Q2 | Working capital | 325.5 million euros | 16 |
| 2025-08-12 | 2025-Q2 | Revenue share abroad | 73.6% | 16 |
| 2025-08-12 | 2025-Q2 | Order backlog | 612.7 million euros | 16 |
| 2025-08-12 | 2025-Q2 | Leverage | 2.0x | 16 |
| 2025-08-12 | 2025-Q2 | Equity ratio | 58.3% | 16 |
| 2025-08-12 | 2025-Q2 | Cash conversion rate | 54.9% | 16 |
| 2025-08-12 | 2025-Q2 | Book-to-bill ratio | 0.95 | 16 |
| 2025-05-12 | 2025-Q1 | Working capital | 320.0 (EUR millions) | 17 |
| 2025-05-12 | 2025-Q1 | Order backlog | 622.2 (EUR millions) | 17 |
| 2025-05-12 | 2025-Q1 | Net debt | 382.2 (EUR millions) | 17 |
| 2025-05-12 | 2025-Q1 | Leverage (net debt/EBITDA) | 1.8x | 17 |
| 2025-05-12 | 2025-Q1 | Gross margin | 30.9 percent | 17 |
| 2025-05-12 | 2025-Q1 | Equity ratio | 57.7 percent | 17 |
| 2025-05-12 | 2025-Q1 | EBITDA margin | 14.9 percent | 17 |
| 2025-05-12 | 2025-Q1 | EBIT margin | 6.9 percent | 17 |
| 2025-05-12 | 2025-Q1 | Cash conversion rate | 79.8 percent | 17 |
| 2025-05-12 | 2025-Q1 | Book-to-bill ratio | 0.84 | 17 |
| 2025-03-31 | 2025-Q1 | Order backlog | 622.2 (EUR in million euros) | 25 |
| 2025-03-19 | FY2024 | Working capital ratio | 28.6 | 15 |
| 2025-03-19 | FY2024 | Working capital | 318.8 (EUR million euros) | 15 |
| 2025-03-19 | FY2024 | Work related illnesses | 0 | 15 |
| 2025-03-19 | FY2024 | Women supervisory board | 50 percent | 15 |
| 2025-03-19 | FY2024 | Women ratio | 30.3 | 15 |
| 2025-03-19 | FY2024 | Women in mid-senior management count | 11 | 15 |
| 2025-03-19 | FY2024 | Women in mid-senior management | 30.6 % | 15 |
| 2025-03-19 | FY2024 | Women first management level | 29.2 percent | 15 |
| 2025-03-19 | FY2024 | Trainees and Dual Study Students | 178 | 15 |
| 2025-03-19 | FY2024 | Trainees | 178 | 15 |
| 2025-03-19 | FY2024 | Total Training Hours | 27,524 hours | 15 |
| 2025-03-19 | FY2024 | Total Opex Prior Year | 86.3 million euros | 15 |
| 2025-03-19 | FY2024 | Total Opex | 92.0 million euros | 15 |
| 2025-03-19 | FY2024 | Total Indirect Scope 3 Greenhouse Gas Emissions 2024 | 285,705 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Total Greenhouse Gas Emissions Site-Specific 2024 | 304,391 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Total Greenhouse Gas Emissions Market-Specific 2024 | 290,198 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Total Family Leave Utilization % | 5.5 % | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Revenue Share Prior Year | 38.7 % | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Revenue Share | 37.4 % | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Opex Share | 40.8 % | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Opex Share Prior Year | 37.6 million euros | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Opex | 37.5 million euros | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Capex Share | 57.6 % | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Capex Prior Year | 41.1 million euros | 15 |
| 2025-03-19 | FY2024 | Taxonomy-Eligible Capex | 66.0 million euros | 15 |
| 2025-03-19 | FY2024 | Site-Specific Scope 2 Greenhouse Gas Emissions 2024 | 16,190 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 3 Category 2 Capital Goods 2024 | 33,750 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 3 Category 11 Use of Sold Products 2024 | 54,945 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 3 Category 1 goods and services purchased 2024 | 197,010 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 1 greenhouse gas emissions 2024 | 2,496 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 1 greenhouse gas emissions 2019 | 2,254 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 1 and market-based Scope 2 combined 2024 | 4,493 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 1 and market-based Scope 2 combined 2023 | 5,031 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Scope 1 and market-based Scope 2 combined 2019 | 10,161 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Reportable occupational accidents | 36 | 15 |
| 2025-03-19 | FY2024 | Personnel expenses | 399.6 (EUR million euros) | 15 |
| 2025-03-19 | FY2024 | Payout ratio on earnings | 23.5² | 15 |
| 2025-03-19 | FY2024 | Pay ratio highest to median | 22 | 15 |
| 2025-03-19 | FY2024 | Other compliance reports | 16 | 15 |
| 2025-03-19 | FY2024 | Order intake | 1,027.7 (EUR million euros) | 15 |
| 2025-03-19 | FY2024 | Order backlog | 670.1 (EUR million euros) | 15 |
| 2025-03-19 | FY2024 | Occupational accident rate per million hours | 4.9 | 15 |
| 2025-03-19 | FY2024 | New trainees and dual study students hired | 64 | 15 |
| 2025-03-19 | FY2024 | Men in mid-senior management count | 25 | 15 |
| 2025-03-19 | FY2024 | Men in mid-senior management | 69.4 % | 15 |
| 2025-03-19 | FY2024 | Market-based Scope 2 greenhouse gas emissions 2024 | 1,997 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Market-based Scope 2 greenhouse gas emissions 2019 | 2,778 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Male employees family leave utilization % | 4.7 % | 15 |
| 2025-03-19 | FY2024 | Male employees family leave utilization | 129 | 15 |
| 2025-03-19 | FY2024 | Leverage | 1.8 | 15 |
| 2025-03-19 | FY2024 | Interns | 26 | 15 |
| 2025-03-19 | FY2024 | independent shareholder representatives | 83.3 percent | 15 |
| 2025-03-19 | FY2024 | gross profit margin | 33.4 | 15 |
| 2025-03-19 | FY2024 | fines penalties corruption | 0 | 15 |
| 2025-03-19 | FY2024 | female employees family leave utilization percentage | 7.6 % | 15 |
| 2025-03-19 | FY2024 | female employees family leave utilization | 82 | 15 |
| 2025-03-19 | FY2024 | fatal occupational accidents | 0 | 15 |
| 2025-03-19 | FY2024 | Equity ratio | 55.6 | 15 |
| 2025-03-19 | FY2024 | Dividend yield | 1.7² | 15 |
| 2025-03-19 | FY2024 | Dividend per share | 0.38² | 15 |
| 2025-03-19 | FY2024 | discrimination and harassment reports | 7 | 15 |
| 2025-03-19 | FY2024 | Debt-to-equity ratio | 0.80 | 15 |
| 2025-03-19 | FY2024 | corruption incidents | 0 | 15 |
| 2025-03-19 | FY2024 | collective agreement coverage percentage | 43.8 % | 15 |
| 2025-03-19 | FY2024 | collective agreement coverage headcount | 2,033 | 15 |
| 2025-03-19 | FY2024 | Cash conversion rate | 46.5 | 15 |
| 2025-03-19 | FY2024 | capital expenditure | 114.6 (EUR millions) | 12 |
| 2025-03-19 | FY2024 | book to bill ratio total | 0.92 | 15 |
| 2025-03-19 | FY2024 | book to bill ratio SMS | 1.03 | 15 |
| 2025-03-19 | FY2024 | book to bill ratio NPPC | 0.70 | 15 |
| 2025-03-19 | FY2024 | book to bill ratio APS | 0.94 | 15 |
| 2025-03-19 | FY2024 | Book-to-bill ratio | 0.70 | 15 |
| 2025-03-19 | FY2024 | average training hours total | 5.92 | 15 |
| 2025-03-19 | FY2024 | average supervisory board length of service | 4.0 years | 15 |
| 2025-03-19 | FY2024 | average supervisory board age | 52.5 years | 15 |
| 2025-03-19 | FY2024 | agency workers | 38 | 15 |
| 2025-03-19 | FY2024 | absenteeism rate | 5.8 | 15 |
| 2025-03-19 | FY2024 | Working capital | 318,760 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | Training rate | 3.8 % | 15 |
| 2025-03-19 | FY2024 | Total energy consumption | 68,512 | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Total comprehensive income | 3,639 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Revenue | 31,446 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Other comprehensive income | 319 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Non-current liabilities | 265 | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Non-current assets | 1,562 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Net assets | 7,811 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Earnings after tax | 3,320 | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Current liabilities | 9,256 | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Current assets | 15,771 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Cash flows from operating activities | 5,664 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | TRIOPTICS China Hong Kong Cash flows from financing activities | -2,777 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | ROCE | 10.8 | 15 |
| 2025-03-19 | FY2024 | R&D ratio 2 | 5.7 | 15 |
| 2025-03-19 | FY2024 | R&D ratio 1 | 9.5 | 15 |
| 2025-03-19 | FY2024 | R&D output | 106.5 | 15 |
| 2025-03-19 | FY2024 | R&D expenses | 64.0 (EUR million euros) | 15 |
| 2025-03-19 | FY2024 | Portion of green electricity | 95.8 % | 15 |
| 2025-03-19 | FY2024 | Plan assets | 136,078 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | Organic revenue growth | 4.7% | 15 |
| 2025-03-19 | FY2024 | Order backlog | 670,079 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | Indirect emissions Scope 2 | 1,997 t CO2eq | 15 |
| 2025-03-19 | FY2024 | GHG emissions per 1 million euros revenue (site-specific) | 27.3 t CO2eq/million euros | 15 |
| 2025-03-19 | FY2024 | GHG emissions per 1 million euros revenue (market-specific) | 26.0 t CO2eq/million euros | 15 |
| 2025-03-19 | FY2024 | GHG emissions Scope 1+2 | 4,493 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Free cash flow | 102.9 million | 15 |
| 2025-03-19 | FY2024 | Equity ratio | 55.6 | 15 |
| 2025-03-19 | FY2024 | Engagement score | 76 % | 15 |
| 2025-03-19 | FY2024 | Energy intensity per net revenue | 61.4 (EUR MWh/currency unit) | 15 |
| 2025-03-19 | FY2024 | EBITDA margin | 19.9 % | 12 |
| 2025-03-19 | FY2024 | EBITDA margin | 19.9 | 15 |
| 2025-03-19 | FY2024 | EBITDA margin | 19.9 | 15 |
| 2025-03-19 | FY2024 | EBITDA | 221.5 (EUR millions) | 12 |
| 2025-03-19 | FY2024 | EBITDA | 221.5 million | 15 |
| 2025-03-19 | FY2024 | EBIT margin | 13.1 | 15 |
| 2025-03-19 | FY2024 | EBIT margin | 13.1 | 15 |
| 2025-03-19 | FY2024 | Dividend per share | 0.38 euros | 15 |
| 2025-03-19 | FY2024 | Direct emissions Scope 1 | 2,496 t CO2eq | 15 |
| 2025-03-19 | FY2024 | Defined benefit obligations (DBO) | 143,198 | 15 |
| 2025-03-19 | FY2024 | Contract liabilities | 60,308 | 15 |
| 2025-03-19 | FY2024 | Contract assets | 86,835 (EUR in thousand euros) | 15 |
| 2025-03-19 | FY2024 | Cash conversion rate | 46.5 | 15 |
| 2025-03-19 | FY2024 | CSR rate | 60.9 % | 15 |
| 2025-03-19 | FY2024 | CSR rate | 61 percent | 15 |
| 2025-03-19 | FY2024 | CO₂ reduction vs. base year 2019 | 55.8 % | 15 |
| 2025-03-25 | 2024-Q4 | Order backlog | 670.1 (EUR in million euros) | 14 |
| 2024-11-11 | 2024-Q3 | Working capital ratio | 30.1 | 11 |
| 2024-11-11 | 2024-Q3 | Working capital | 335.3 (EUR in million euros) | 11 |
| 2024-11-11 | 2024-Q3 | R&D output | 77.5 | 11 |
| 2024-11-11 | 2024-Q3 | Order backlog | 709.2 (EUR in million euros) | 11 |
| 2024-11-11 | 2024-Q3 | Leverage (net debt/EBITDA) | 1.9 (EUR x) | 11 |
| 2024-11-11 | 2024-Q3 | Gross margin | 33.9 | 11 |
| 2024-11-11 | 2024-Q3 | Equity ratio | 55.9 | 11 |
| 2024-11-11 | 2024-Q3 | EBITDA margin | 19.7 | 11 |
| 2024-11-11 | 2024-Q3 | EBIT margin | 12.8 | 11 |
| 2024-11-11 | 2024-Q3 | Cash conversion rate | 38.8 | 11 |
| 2024-11-11 | 2024-Q3 | Book-to-bill ratio | 0.96 | 11 |
| 2024-08-09 | 2024-H1 | Order backlog | 734.1 (EUR in million euros) | 13 |
| 2024-08-09 | 2024-H1 | EBITDA margin | 18.8 | 13 |
| 2024-08-09 | 2024-H1 | EBIT margin | 11.8 | 13 |
| 2024-08-09 | 2024-H1 | Cash conversion rate | 40.9 | 13 |
| 2024-08-08 | 2024-Q2 | Working capital ratio | 29.2 | 9 |
| 2024-08-08 | 2024-Q2 | Working capital | 321.6 (EUR in million euros) | 9 |
| 2024-08-08 | 2024-Q2 | Order backlog | 734.1 (EUR in million euros) | 9 |
| 2024-08-08 | 2024-Q2 | Leverage net debt EBITDA | 2.0x | 9 |
| 2024-08-08 | 2024-Q2 | Equity ratio | 54.2 | 9 |
| 2024-08-08 | 2024-Q2 | Cash conversion rate | 40.9 | 9 |
| 2024-08-08 | 2024-Q2 | Book-to-bill ratio | 0.97 | 9 |
| 2024-08-08 | 2024-Q2 | EBITDA margin | 18.8 | 9 |
| 2024-08-08 | 2024-Q2 | EBIT margin | 11.8 | 9 |
| 2024-05-07 | 2024-Q1 | Working capital | 312.9 (EUR in million euros) | 10 |
| 2024-05-07 | 2024-Q1 | Order backlog | 731.3 (EUR in million euros) | 10 |
| 2024-05-07 | 2024-Q1 | Leverage (net debt to EBITDA) | 1.9x | 10 |
| 2024-05-07 | 2024-Q1 | Equity ratio | 54.3 | 10 |
| 2024-03-27 | FY2023 | Order backlog | 745.0 (EUR in million euros) | 5 |
| 2024-03-15 | FY2023 | Workplace accidents group | 5.5 | 8 |
| 2024-03-15 | FY2023 | Workplace accidents Germany | 11.6 | 8 |
| 2024-03-15 | FY2023 | Working capital | 304.4 (EUR in million euros) | 8 |
| 2024-03-15 | FY2023 | Women career index score | 86 | 8 |
| 2024-03-15 | FY2023 | Water consumption | 92,444 | 8 |
| 2024-03-15 | FY2023 | Waste recycling rate | 38.6 | 8 |
| 2024-03-15 | FY2023 | Trainees employed | 163 | 8 |
| 2024-03-15 | FY2023 | Trainee retention rate | 88.0 | 8 |
| 2024-03-15 | FY2023 | Taxonomy-Eligible Revenue Share | 38.7 | 8 |
| 2024-03-15 | FY2023 | Taxonomy-eligible revenue | 412.1 (EUR million euros) | 8 |
| 2024-03-15 | FY2023 | Taxonomy-Eligible Opex Share | 43.6 | 8 |
| 2024-03-15 | FY2023 | Taxonomy-Eligible Opex | 37.6 (EUR million euros) | 8 |
| 2024-03-15 | FY2023 | Taxonomy-Eligible Capex Share | 37.3 | 8 |
| 2024-03-15 | FY2023 | Taxonomy-Eligible Capex | 41.1 (EUR million euros) | 8 |
| 2024-03-15 | FY2023 | Scope 3 emissions | around 300,000 | 8 |
| 2024-03-15 | FY2023 | parental leave germany | 155 | 8 |
| 2024-03-15 | FY2023 | order backlog recognition 2024 | 86.7 (EUR %) | 4 |
| 2024-03-15 | FY2023 | Order backlog | 744.9 (EUR in million euros) | 8 |
| 2024-03-15 | FY2023 | non-hazardous waste | 1,127 | 8 |
| 2024-03-15 | FY2023 | hazardous waste | 195 | 8 |
| 2024-03-15 | FY2023 | green electricity proportion | 93.6 | 8 |
| 2024-03-15 | FY2023 | Equity ratio | 54.2 | 8 |
| 2024-03-15 | FY2023 | energy efficiency | 63.3 | 8 |
| 2024-03-15 | FY2023 | energy consumption | 67,477 | 8 |
| 2024-03-15 | FY2023 | cash conversion rate 2023 | 60.8 | 4 |
| 2024-03-15 | FY2023 | Cash conversion rate | 60.8 | 8 |
| 2024-03-15 | FY2023 | ROCE | 9.6 percent | 8 |
| 2024-03-15 | FY2023 | R&D ratio | 8.9 percent | 8 |
| 2024-03-15 | FY2023 | R&D expenses to revenue | 5.7 percent | 8 |
| 2024-03-15 | FY2023 | Order backlog | 745.0 (EUR million euros) | 8 |
| 2024-03-15 | FY2023 | Gross margin | 34.8 percent | 8 |
| 2024-03-15 | FY2023 | Equity ratio | 54.2 | 8 |
| 2024-03-15 | FY2023 | EBITDA margin guidance 2024 | 19.5 to 20.0 | 4 |
| 2024-03-15 | FY2023 | EBITDA margin 2023 | 19.7 | 4 |
| 2024-03-15 | FY2023 | EBITDA margin | 19.7 | 8 |
| 2024-03-15 | FY2023 | EBITDA margin | 19.7 | 8 |
| 2024-03-15 | FY2023 | EBIT margin | 11.9 | 8 |
| 2024-03-15 | FY2023 | Cash conversion rate | 60.8 | 8 |
| 2024-03-15 | FY2023 | CSR rate | 49.0 | 8 |
| 2024-03-15 | FY2023 | CO2 emissions scope 1+2 | 5,031 | 8 |
| 2024-03-15 | FY2023 | CO2 emissions reduction vs. 2019 | 50.5 | 8 |
| 2024-03-15 | FY2023 | Book-to-bill ratio | 1.02 | 8 |
| 2023-11-08 | 2023-Q3 | Working capital ratio | 30.7% | 2 |
| 2023-11-08 | 2023-Q3 | Leverage (net debt to EBITDA) | 2.3 (EUR millions) | 2 |
| 2023-11-08 | 2023-Q3 | Equity ratio | 52.3% | 2 |
| 2023-11-08 | 2023-Q3 | EBITDA margin | 18.6% | 2 |
| 2023-11-08 | 2023-Q3 | Cash conversion rate | 39.8% | 2 |
| 2023-11-08 | 2023-Q3 | Book-to-bill ratio | 1.09 | 2 |
| 2023-09-30 | 2023-Q3 | Order backlog | 794.9 (EUR in million euros) | 7 |
| 2023-09-30 | 2023-Q3 | EBITDA margin (Jul.-Sep. 2023) | 19.5% | 7 |
| 2023-09-30 | 2023-Q3 | EBITDA margin (Jul.-Sep. 2022) | 19.2% | 7 |
| 2023-09-30 | 2023-Q3 | EBITDA margin (Jan.-Sep. 2023) | 18.6% | 7 |
| 2023-09-30 | 2023-Q3 | EBITDA margin (Jan.-Sep. 2022) | 16.9% | 7 |
| 2023-09-30 | 2023-Q3 | EBIT margin (Jul.-Sep. 2023) | 13.0% | 7 |
| 2023-09-30 | 2023-Q3 | EBIT margin (Jul.-Sep. 2022) | 12.6% | 7 |
| 2023-09-30 | 2023-Q3 | EBIT margin (Jan. - Sept. 2023) | 11.5% | 7 |
| 2023-09-30 | 2023-Q3 | EBIT margin (Jan. - Sept. 2022) | 9.8% | 7 |
| 2023-09-30 | 2023-Q3 | Cash conversion rate (July - Sept. 2023) | 59.7% | 7 |
| 2023-09-30 | 2023-Q3 | Cash conversion rate (July - Sept. 2022) | 32.6% | 7 |
| 2023-09-30 | 2023-Q3 | Cash conversion rate (Jan. - Sept. 2023) | 39.8% | 7 |
| 2023-09-30 | 2023-Q3 | Cash conversion rate (Jan. - Sept. 2022) | 24.1% | 7 |
| 2023-08-08 | 2023-Q2 | Working capital ratio | 30.2% | 1 |
| 2023-08-08 | 2023-Q2 | Leverage (net debt/EBITDA) | 2.4 (EUR thousands) | 1 |
| 2023-08-08 | 2023-Q2 | Equity ratio | 50.9% | 1 |
| 2023-08-08 | 2023-Q2 | EBITDA margin | 18.1% | 1 |
| 2023-08-08 | 2023-Q2 | EBIT margin | 10.7% | 1 |
| 2023-08-08 | 2023-Q2 | Cash conversion rate | 28.5% | 1 |
| 2023-08-08 | 2023-Q2 | Book-to-bill ratio | 1.08 | 1 |
| 2023-05-10 | 2023-Q1 | Working capital | 283.2 (EUR in million euros) | 3 |
| 2023-05-10 | 2023-Q1 | Order backlog | 776.1 (EUR in million euros) | 3 |
| 2023-05-10 | 2023-Q1 | Net debt | 465.5 (EUR in million euros) | 3 |
| 2023-05-10 | 2023-Q1 | Leverage | 2.3 | 3 |
| 2023-05-10 | 2023-Q1 | Equity ratio | 50.6% | 3 |
| 2023-05-10 | 2023-Q1 | EBITDA margin | 15.6% | 3 |
| 2023-05-10 | 2023-Q1 | Cash conversion rate | 78.0% | 3 |
| 2023-05-10 | 2023-Q1 | Book-to-bill ratio | 1.21 | 3 |
Guidance Tracking (latest per metric/period · 7/14)#
All management forecasts (guidance) and their later outcome. Types: fiscal-year targets as well as quarterly/half-year targets; per metric and period the most recent statement applies, older versions can be expanded. The status is checked automatically against the actuals reported later: open (period still running), met, beaten, missed. For ranges (“X to Y”) reaching the range counts. Logged neutrally, no estimate of our own, no assessment.
Actuals: revenue in €m · ratios in %
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-08-11 | Revenue | upper half of single-digit percentage range | – | pending | raised | 28 |
| FY2026 | 2026-08-11 | EBITDA margin | 20–21% | – | pending | raised | 28 |
| FY2026 | 2026-05-11 | Capex | 77.4 | – | pending | confirmed | 28 |
| FY2026 | – | EBITDA | 19–21 | – | pending | raised | 22 |
| FY2025 | 2025-11-11 | Capex | 114.6 | 77.4 | miss | cut | 18 |
| FY2025 | 2025-11-11 | EBITDA margin | 18–19.5% | 18.4 | in line | confirmed | 18 |
| FY2025 | 2025-05-12 | Revenue | 5 | 1,046 | – | confirmed | 18 |
| FY2024 | 2024-05-07 | Revenue | mid-single-digit percentage range | 1,115.8 | – | confirmed | 11 |
| FY2024 | 2024-03-15 | Capex | Slightly above prior-year level | 114.6 | – | initiated | 4 |
| FY2024 | 2024-03-15 | EBITDA | 19.5–20 | 221.5 | – | initiated | 4 |
| FY2024 | 2024-03-15 | EBITDA margin | 19.5–20% | 19.9 | in line | confirmed | 11 |
| FY2024 | 2024-03-15 | cash_conversion_rate | 50 | – | – | initiated | 4 |
| FY2023 | 2023-11-08 | EBITDA margin | 19.5% | 19.7 | beat | raised | 8 |
| FY2023 | 2023-05-10 | Revenue | 1,050–1,100 | 1,066 | in line | confirmed | 8 |
Development#
A condensed summary per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. Most recent period first, grouped by year; each text is written from the original report of that period, superscript numbers lead to the source.
FY2026
In the first half of fiscal year 2026, Jenoptik reported revenue of 241.2 million euros in Q1 and 262 million euros in Q2, with Semiconductor & Advanced Manufacturing as the primary growth driver in both quarters while Biophotonics and Metrology & Production Solutions experienced revenue declines 29 28. Order intake rose 74.4% to 356.9 million euros in Q1 29, and cumulative H1 order intake reached 723.4 million euros, a 53.0% increase year on year, lifting the order backlog to 824.8 million euros with a book-to-bill ratio of 1.44 at end of Q2 28. Net income was 16.8 million euros in Q1 29 and 22.9 million euros in Q2 28, with the EBITDA margin expanding from 15.8% in the prior-year second quarter to 19.7% in Q2 2026 28. The Executive Board raised its full-year guidance in Q2 to expect revenue in the upper half of the previous single-digit percentage range and an EBITDA margin of 20.0-21.0% 28.
FY2025
Jenoptik generated full-year 2025 revenue of 1,046 million euros, a decline of 6.3 percent year-over-year, reflecting weaker demand in the semiconductor equipment supply chain and the challenging North American automotive market 27. Effective January 1, 2025, the group reorganized into four Strategic Business Units (Semiconductor & Advanced Manufacturing, Biophotonics, Metrology & Production Solutions, and Smart Mobility Solutions), replacing the prior matrix structure; Biophotonics and Smart Mobility Solutions delivered revenue growth while the other two units reported lower sales 27. Net income came in at 74.2 million euros, with diluted earnings per share of 1.26 euros; earnings per share declined 22.2 percent compared with the prior year 23. The EBITDA margin stood at 18.4 percent for the full year, within the forecast range, as cost-reduction measures partially offset the revenue decline 27. Free cash flow before interest and taxes improved approximately 50 percent to 152.4 million euros, aided by higher operating cash flows and reduced capital expenditure following completion of the Dresden micro-optics factory; the equity ratio strengthened to 60.2 percent and net debt-to-EBITDA leverage improved to 1.6 times from 1.8 times 27.
FY2024
Jenoptik grew full-year revenue by 4.7% to 1,115.8 million euros in 2024, driven primarily by the Advanced Photonic Solutions division, particularly in the semiconductor equipment business 15. The EBITDA margin for the year reached 19.9%, finishing at the upper end of the guidance range of 19.5 to 20.0 percent 15. Diluted earnings per share increased 27.6% to 1.62 euros, while full-year free cash flow was lower than the prior year, largely due to higher capital expenditure for the new cleanroom factory in Dresden 15. Order intake declined 5.9% to 1,027.7 million euros and the order backlog decreased to 670.1 million euros from 745.0 million euros at year-end 2023 15. In November 2024, the Group announced it was postponing previously communicated 2025 financial targets to 2026, citing a challenging market environment 11.
FY2023
Jenoptik AG grew full-year revenue organically by 8.7 percent to 1,066 million euros in 2023, with particularly strong demand in the semiconductor equipment business within the Advanced Photonic Solutions division 8. EBITDA reached 209.6 million euros with a margin of 19.7 percent, up from 18.8 percent in 2022, while net income rose 28.8 percent to 73.5 million euros 5 8. The Advanced Photonic Solutions division was the primary revenue driver, reaching 821.2 million euros with an EBITDA margin of 21.9 percent, while Non-Photonic Portfolio Companies reported EBITDA of 17.6 million euros versus 3.6 million euros in the prior year 8. Net debt declined to 423.1 million euros from 479.0 million euros in the prior year, with the net debt to EBITDA leverage ratio improving to 2.0 from 2.6 and the equity ratio reaching 54.2 percent 8. For 2024, management guided organic revenue growth in the mid-single-digit percentage range and an EBITDA margin of 19.5 to 20.0 percent, noting an approximately 0.5 percentage point charge for the planned Dresden facility relocation 8.
Glossary#
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: official investor relations documents#
All original documents used, with type (e.g. quarterly, half-year, annual report), publication date and a direct link to the filing (EDINET/SEC/IR). Every superscript number in the report points to an entry in this list; so every figure can be traced back to its place in the original.
| # | Document type | Published | Link |
|---|---|---|---|
| #3 / #103 | IR-Quarter | – | Open |
| #6 | IR-Half | – | Open |
| #8 / #108 | IR-Annual | – | Open |
| #10 / #110 | IR-Quarter | – | Open |
| #13 | IR-Half | – | Open |
| #17 / #117 | IR-Quarter | – | Open |
| #20 | IR-Report | – | Open |
| #22 | IR-Report | – | Open |
| #23 | IR-Report | – | Open |
| #29 / #129 | IR-Quarter | – | Open |
| #1 / #101 | IR-Quarter | 2023-08-08 | Open |
| #7 | IR-Quarter | 2023-09-30 | Open |
| #2 / #102 | IR-Quarter | 2023-11-08 | Open |
| #4 | IR-Annual | 2024-03-15 | Open |
| #5 | IR-Annual | 2024-03-27 | Open |
| #9 / #109 | IR-Quarter | 2024-08-08 | Open |
| #11 / #111 | IR-Quarter | 2024-11-11 | Open |
| #12 | IR-Annual | 2025-03-19 | Open |
| #15 / #115 | IR-Annual | 2025-03-19 | Open |
| #14 | IR-Report | 2025-03-25 | Open |
| #25 | IR-Report | 2025-03-31 | Open |
| #16 / #116 | IR-Quarter | 2025-08-12 | Open |
| #24 | IR-Half | 2025-08-13 | Open |
| #18 / #118 | IR-Quarter | 2025-11-11 | Open |
| #26 | IR-Quarter | 2025-11-12 | Open |
| #19 | IR-Report | 2026-03-18 | Open |
| #21 | IR-Report | 2026-03-18 | Open |
| #27 / #127 | IR-Annual | 2026-03-18 | Open |
| #28 / #128 | IR-Quarter | 2026-08-11 | Open |
FAQ#
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does Jenoptik AG report?
As reported for Q2 2026: Order backlog, EBITDA margin, Equity ratio, Cash conversion rate, EBIT margin, Book-to-bill ratio. The chapter Reported KPIs lists every value with its source. Revenue is broken down by Semiconductor & Advanced Manufacturing, Biophotonics, Metrology & Production Solutions, Smart Mobility Solutions.
Does Jenoptik AG pay a dividend?
The filings report on the dividend; most recent entry: dividend per share 0.40² (FY2025) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of Jenoptik AG?
The sources chapter links all 43 original filings used (IR documents) with type, publication date and a direct link; every figure in the report carries a source number.